Welcome to our dedicated page for CVLB news (Ticker: CVLB), a resource for investors and traders seeking the latest updates and insights on CVLB stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CVLB's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CVLB's position in the market.
Conversion Labs has rebranded itself as LifeMD, Inc., trading under the new ticker symbol LFMD on Nasdaq. This change reflects the company's transformation from a healthcare marketing business to a provider of direct-to-patient telehealth services. LifeMD aims to revolutionize healthcare accessibility with its new subscription-based primary care service. In its preliminary 2020 results, the company reported a 205% revenue increase to $38 million, and anticipates an annual recurring revenue of $26 million, up 525% year-over-year.
Conversion Labs (NASDAQ: CVLB), a leading telehealth company, will present at the BTIG Virtual MedTech Conference from February 17-19, 2021. CEO Justin Schreiber and CBO Corey Deutsch will lead a fireside chat on February 18 at 1:00 PM ET. The event will include virtual meetings with institutional investors. The company recently announced plans to rebrand as LifeMD on February 22, introducing subscription-based primary care services. 2020 saw a 205% revenue increase to $38 million, with a projected annual recurring revenue of $26 million.
Conversion Labs, Inc (NASDAQ: CVLB) has completed a $14 million unregistered private placement to support the nationwide launch of its telehealth services. The company will rebrand as Life MD™ on February 22, enhancing its focus on subscription-based primary care and concierge services. Conversion Labs reported a 205% revenue growth in 2020, reaching $38 million, with an annual recurring revenue projected at $26 million. The funds will expand the telehealth pipeline and customer acquisition strategies.
Conversion Labs (CVLB) has appointed Marc Benathen as chief financial officer, effective March 1, succeeding Juan Manuel Piñeiro Dagnery. Benathen brings 18 years of experience in finance and operations, formerly serving at Blink Fitness and Ann, Inc. His background includes overseeing significant capital market transactions and supporting company growth. CEO Justin Schreiber expressed confidence in Benathen's abilities, highlighting his relevance to Conversion Labs’ expansion in the telemedicine sector.
Conversion Labs (NASDAQ: CVLB) has increased its ownership stake in LegalSimpli Software from 51% to 82.6% by converting long-term debt into equity. LegalSimpli, which operates PDFSimpli.com, is generating annualized revenue exceeding $18 million. CEO Justin Schreiber highlighted the impressive growth since their initial investment in 2018, driven by management's talent and the shift towards subscription-based online services. The company is exploring strategic alternatives for this subsidiary while focusing on its telemedicine growth opportunities through brands like Rex MD and Shapiro MD.
Conversion Labs, Inc. (NASDAQ: CVLB) announced significant financial growth for Q4 and the full year ending December 31, 2020. Revenue for Q4 is projected at $13.6 million, representing a 265% increase year-over-year, while full-year revenue is expected to reach $38.0 million, up 205% from 2019. December alone generated a record $5.1 million in revenue. Annual recurring revenue (ARR) grew by 525%, totaling $26.0 million. The firm emphasizes its role in expanding telemedicine access and plans to enhance subscription services further in 2021.
Conversion Labs, Inc. (NASDAQ: CVLB) has appointed Dr. Anthony Puopolo as the new chief medical officer. Dr. Puopolo, with over 20 years of healthcare experience, will oversee the company's network of licensed physicians and enhance its telemedicine offerings. Previously, he served as regional medical director at SwiftMD and founded Integrative Wellness Medical Group. His diverse background in primary care and mental health positions him to support Conversion Labs' growth as a leading telemedicine provider.
Conversion Labs, Inc. (NASDAQ: CVLB) has been invited to present at H.C. Wainwright’s BioConnect Conference, scheduled for January 11-14, 2021. The company will discuss its significant achievements, including a record annualized revenue run-rate of $53.9 million and a remarkable 517% increase in annual recurring revenue (ARR) from subscriptions, reaching $23.0 million. Key topics will include the upcoming launch of Nava MD™, its new teledermatology brand. The presentation will be available on-demand, and the company encourages registration for virtual one-on-one meetings with analysts and investors.
Conversion Labs, Inc. (NASDAQ: CVLB) has appointed Bryant Hussey as its chief digital officer. Hussey, who has over 20 years of marketing experience, will focus on enhancing customer retention, launching new telemedicine products, and improving unit economics. Previously at Advanced Vita Supplements, he successfully launched a subscription model, increasing brand awareness. Conversion Labs reported a 517% increase in annual recurring revenue (ARR) from subscriptions, reaching $23 million, driven by demand for its Rex MD product line.
Conversion Labs (NASDAQ: CVLB) reported a record annualized revenue run-rate of $53.9 million in November 2020, up 332% from $12.5 million in 2019. Monthly revenues reached $4.5 million, a 233% increase year-over-year. The annual recurring revenue (ARR) from subscriptions climbed to $23.0 million, a 517% increase from November 2019. The company appointed several key executives, including Eric Yecies as chief compliance officer, and aims to enhance telehealth accessibility and quality. CEO Justin Schreiber emphasizes strong growth and potential for the future.
